Stockscreener 앱 받기
0.4274
15.38%
-0.0777
시간 외 거래:
.42
-0.0074
-1.73%
Karyopharm Therapeutics Inc 주식(KPTI)의 최신 뉴스
Two Acorn funds account for one manager’s reported stake in Karyopharm (KPTI). - Stock Titan
Karyopharm Therapeutics stock falls 13.72 percent as liquidity tightens - AD HOC NEWS
A tax-related sale: Karyopharm (KPTI) accounting chief sells 378 shares at $1.19 each. - Stock Titan
A new Karyopharm hire gets 333 stock units, vesting over 3 years if they stay. - Stock Titan
Karyopharm Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - PR Newswire
Karyopharm Therapeutics (KPTI) Stock News - Stock Titan
More than 5% of Karyopharm Therapeutics (KPTI) is reported under one manager's name, tied to two funds. - Stock Titan
Two partnerships report Karyopharm (KPTI) shares; their manager has shared voting power. - Stock Titan
KPTI Slides As Legal, Cash Pressures Rattle Traders - StocksToTrade
Form 8K Karyopharm Therapeutics Inc For: 11 September By Investing.com - Investing.com South Africa
Karyopharm Skips $15.8 Million Debt Payment, Warns of Going-Concern Risk - Minichart
KPTI Looks 64.4% Undervalued on GF Value™ but Faces Significant Financial Struggles - GuruFocus
Form 8K Karyopharm Therapeutics Inc For: 11 September By Investing.com - Investing.com Canada
Karyopharm TherapeuticsEnters Forbearance Agreement And Waiver On Sept 10, 2026SEC Filing - TradingView
Karyopharm Wins Forbearance to Oct. 15, Will Issue $20M 0% Convertible Preferred - TradingView
Karyopharm pushes off debt payment; Amgen eyes broader Imdelltra use - Yahoo Finance
Karyopharm Therapeutics Stock Price Forecast. Should You Buy KPTI? - StockInvest.us
Israel Englander group discloses new Karyopharm stake (NASDAQ: KPTI) - Stock Titan
Karyopharm Therapeutics (KPTI) Stock Fair Value Falls After Split Analyst Views On Trial Updates - Yahoo Finance
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Karyopharm
Karyopharm Seeks FDA Approval for XPOVIO Plus Ruxolitinib in Myelofibrosis - Cure Today
A Second Drug for a Disease That Has Only Ever Had One: Karyopharm Files for Selinexor Plus Ruxolitinib in Myelofibrosis - Onco'Zine
Karyopharm Therapeutics Submits Supplemental New Drug Application to the Fda for Xpovio Plus Ruxolitinib for Patients with Myelofibrosis - marketscreener.com
Karyopharm Therapeutics submits sNDA seeking accelerated approval for selinexor plus ruxolitinib in myelofibrosis - TradingView
KPTI Looks 60.5% Undervalued on GF Value™ Amid Challenging Funda - GuruFocus
Karyopharm Submits Supplemental New Drug Application to the FDA for XPOVIO® (selinexor) Plus Ruxolitinib for Patients with Myelofibrosis - Karyopharm
Karyopharm Submits Supplemental New Drug Application to the FDA for XPOVIO® (selinexor) Plus Ruxolitinib for Patients with Myelofibrosis - TradingView
Karyopharm Submits Supplemental New Drug Application to the FDA for XPOVIO® (selinexor) Plus Ruxolitinib for Patients with Myelofibrosis - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Karyopharm Therapeutics Inc.KPTI - FinancialContent
Karyopharm’s (KPTI) Big Cancer Bet Faces A Ticking Clock - Yahoo Finance
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Karyopharm Therapeutics Inc.KPTI - YCharts
Karyopharm (KPTI) Q2 2026 Earnings Call Transcript - AOL.com
KPTI Stock Price and Chart — NASDAQ:KPTI - TradingView
Earnings Release: Here's Why Analysts Cut Their Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Price Target To US$6.40 - simplywall.st
Earnings Release: Here's Why Analysts Cut Their Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Price Target To US$6.40 - simplywall.st
RA Capital boosts Karyopharm (KPTI) stake to 9.99% beneficial ownership cap - Stock Titan
Karyopharm Therapeutics (KPTI): Commodore Capital now reports 0.0% ownership - Stock Titan
Karyopharm Therapeutics Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Conferencia de resultados del 2T de 2026 de Karyopharm (KPTI): foco en la sNDA de selinexor y la liquidez - TradingKey
Karyopharm (KPTI) Ergebniskonferenz Q2 2026: Fokus auf Selinexor-sNDA und Liquidität - TradingKey
Karyopharm Therapeutics Inc (KPTI) Earnings, Actual EPS, EPS Estimates & Results - Stocktwits
Karyopharm Therapeutics Inc (KPTI) (Q2 2026) Earnings Call Highlights: SENTRY Trial Success and ... - Yahoo! Finance Canada
Karyopharm Therapeutics Inc (KPTI) (Q2 2026) Earnings Call Highl - GuruFocus
It's crunch time for Karyopharm as company faces potential default next month - Fierce Pharma
Karyopharm Therapeutics has cash to last only into next month - The Business Journals
Karyopharm Therapeutics Releases Q2 2026 Financial Results - AlphaStreet
Karyopharm Q2 2026 slides: myelofibrosis sNDA planned for August By Investing.com - Investing.com Australia
Karyopharm Q2 2026 slides: myelofibrosis sNDA planned for August By Investing.com - Investing.com India
Karyopharm Therapeutics Q2 2026 Earnings Call Transcript - marketbeat.com
4.80%
자본화:
|
볼륨(24시간):